Long-term Safety Data for JAK Inhibitors in Atopic Dermatitis

EP: 1.JAK Inhibitors and Pathophysiology of Atopic Dermatitis

EP: 2.Oral JAK inhibitors and Their Use for Treatment of Atopic Dermatitis

EP: 3.Oral JAK Inhibitor Use in Atopic Dermatitis: Screening and Monitoring Patients

Now Viewing

EP: 4.Long-term Safety Data for JAK Inhibitors in Atopic Dermatitis

EP: 5.Utilizing Long-Term Atopic Dermatitis Data in Clinical Practice

EP: 6.Data on Early Itch Relief with JAK Inhibitors in Atopic Dermatitis

EP: 7.Speed of Itch Relief in Atopic Dermatitis

EP: 8.Systemic Treatments and Switching Therapy in Atopic Dermatitis

EP: 9.Treatment Expectations and Patient Conversations in Atopic Dermatitis

EP: 10.Switching from Biologics to JAK Inhibitors in Atopic Dermatitis: Clinical Data

EP: 11.Treatment Breaks and Rescue Treatments in Atopic Dermatitis

EP: 12.Switching patients to JAK Inhibitors in Atopic Dermatitis in Clinical Practice

EP: 13.Treatment Flexibility While on Abrocitinib in Atopic Dermatitis (JADE REGIMEN)

EP: 14.Future Outlook for Atopic Dermatitis Treatments

Video content above is prompted by the following:

1. Please discuss phase 3 and long-term efficacy (International Global Assessment scores, Eczema Area and Severity Index scores, itch relief) and safety data for abrocitinib and upadacitinib in atopic dermatitis (AD).
2. How do the long-term data affect your decision to use oral JAK inhibitors in AD?
3. Do you have any safety concerns that have not been addressed by the long-term data so far?